Results 101 to 110 of about 18,054 (201)
Behandlung der mukokutanen Leishmaniose – eine systematische Übersicht
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 22, Issue 6, Page 763-774, June 2024.Zusammenfassung Die mukokutane Leishmaniose ist eine schwere Infektionskrankheit, die überwiegend in Zentral‐ und Südamerika endemisch ist und sich klinisch mit granulomatösen, destruierenden Schleimhautläsionen im Mund‐Nasen‐Rachenraum manifestiert. Sie wird durch Protozoen, Leishmania spp., ausgelöst, die durch Sandmücken auf den Menschen übertragen ...
Theresa Fischer +3 more
wiley +1 more source
Revue Marocaine des Sciences Agronomiques et Vétérinaires, 2017 Durant 6 mois, 201 spécimens de mammifères sauvages représentant 7 espèces réparties en 6 genres, 4 familles et 3 ordres, dont 2 Genetta angolensis, 3 Nandinia binotata, 10 Galagoides demidoff, 35 Protoxerus strangeri, 73 Funisciurus congicus, 15 Rattus
Matthieu Willy KABAMBA MWAMBA +2 more
doaj
ChemMedChem, Volume 19, Issue 9, May 2, 2024.Several (sub)species of Trypanosoma are responsible for human African trypanosomiasis (HAT), Chagas disease, and Nagana. These (sub)species have different drug susceptibility profiles. This work reports several easily accessed quinolone hydrazides exhibiting sub‐micromolar activities against multiple (sub)species of Trypanosoma.
Kgothatso A. Chirwa +7 more
wiley +1 more source
Fundamental &Clinical Pharmacology, Volume 38, Issue 1, Page 72-83, February 2024.Abstract Human African trypanosomosis (HAT) which is also known as sleeping sickness is caused by Trypanosoma brucei gambiense that is endemic in western and central Africa and T. b. rhodesiense that is endemic in eastern and southern Africa. Drugs used for treatment against HAT first stage have limited effectiveness, and the second stage drugs have ...
Anna Seetsi +5 more
wiley +1 more source
Quercetin as a Promising Antiprotozoan Phytochemical: Current Knowledge and Future Research Avenues
BioMed Research International, Volume 2024, Issue 1, 2024.Despite tremendous advances in the prevention and treatment of infectious diseases, only few antiparasitic drugs have been developed to date. Protozoan infections such as malaria, leishmaniasis, and trypanosomiasis continue to exact an enormous toll on public health worldwide, underscoring the need to discover novel antiprotozoan drugs. Recently, there
Hamed Memariani +3 more
wiley +1 more source
Restriction of the alternative pathway of human complement by intact Trypanosoma brucei subsp. gambiense. [PDF]
, 1986 Dana V. Devine +2 more
openalex +3 more sources
Human African Trypanosomiasis Transmission, Kinshasa, Democratic Republic of Congo
Emerging Infectious Diseases, 2006 To investigate the epidemiology of human African trypanosomiasis (sleeping sickness) in Kinshasa, Democratic Republic of Congo, 2 entomologic surveys were conducted in 2005.
Gustave Simo +7 more
doaj +1 more source
BMC Genomics, 2007 Background In a mammalian host, the cell surface of African trypanosomes is protected by a monolayer of a single variant surface glycoprotein (VSG). The VSG is central to antigenic variation; one VSG gene is expressed at any one time and there is a low ...
Sharma Reuben +6 more
doaj +1 more source
Strategies for Trypanosoma brucei gambiense elimination [PDF]
The Lancet Global Health, 2017 Alison P. Galvani, Abhishek Pandey
openaire +3 more sources
Wild fauna as a probable animal reservoir for Trypanosoma brucei gambiense in Cameroon
Infection, Genetics and Evolution, 2006 In order to study the existence of a wild animal reservoir for Trypanosoma brucei gambiense in South Cameroon, blood was collected from wild animals in three human African trypanosomiasis foci and from a nonendemic control area. The 1142 wild animals sampled belonged to 36 different species pertaining to eight orders (407 primates, 347 artiodactyls ...
Njiokou, F. +6 more
openaire +3 more sources